Bioxcel Therapeutics Inc (BTAI): Canaccord Genuity Reconfirms “Buy” Rating Today, Has a Target of $21.0000/Share

May 17, 2018 - By Tina Thibodeau

Bioxcel Therapeutics Inc (BTAI) Rating Reaffirmed

Canaccord Genuity now has a $21.0000 PT on the $164.90 million market cap company or 99.24 % upside potential. In a research report issued to clients on 16 May, Bioxcel Therapeutics Inc (BTAI) shares have had their “Buy” Rating restate by research professionals at Canaccord Genuity.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Ratings Coverage

Among 5 analysts covering Bioxcel Therapeutics Inc (BTAI), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bioxcel Therapeutics Inc has $2500 highest and $1500 lowest target. $20.40’s average target is 93.55% above currents $10.54 stock price. Bioxcel Therapeutics Inc had 7 analyst reports since April 2, 2018 according to SRatingsIntel. The stock has “Buy” rating by UBS on Monday, April 2. H.C. Wainwright initiated BioXcel Therapeutics, Inc. (NASDAQ:BTAI) on Thursday, May 3 with “Buy” rating. The rating was initiated by BMO Capital Markets on Monday, April 2 with “Buy”. Canaccord Genuity initiated it with “Buy” rating and $2100 target in Monday, April 2 report. The stock has “Buy” rating by Barclays Capital on Monday, April 2.

The stock increased 5.51% or $0.55 during the last trading session, reaching $10.54. About 17,841 shares traded. BioXcel Therapeutics, Inc. (BTAI) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence drug development in the fields of neuroscience and immuno-oncology in the United States. The company has market cap of $164.90 million. The firm is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It currently has negative earnings. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies.

More notable recent BioXcel Therapeutics, Inc. (NASDAQ:BTAI) news were published by: Benzinga.com which released: “32 Stocks Moving In Tuesday’s Mid-Day Session” on April 24, 2018, also Streetinsider.com with their article: “BioXcel Therapeutics (BTAI) Announces Data Presentation at ASCO” published on May 17, 2018, Nasdaq.com published: “BioXcel Therapeutics Announces Acceptance of Abstract at ASCO 2018 Annual Meeting” on April 26, 2018. More interesting news about BioXcel Therapeutics, Inc. (NASDAQ:BTAI) were released by: Globenewswire.com and their article: “BioXcel Therapeutics Announces Data Presentation at ASCO 2018 Annual Meeting” published on May 17, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo’s Woes Abound, Earnings Fail to Boost Amgen” with publication date: April 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.